Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
First Claim
Patent Images
1. A method of reducing a trough effect of a dextromethorphan in a human subject, wherein the human subject is an extensive metabolizer of the dextromethorphan in need of treatment with the dextromethorphan, comprising co-administering to the human subject a daily dose of a combination, wherein the combination comprises:
- 1) a hydroxybupropion, a threohydroxybupropion, an erythrohydroxybupropion or a bupropion, and2) the dextromethorphan,once a day for at least nine consecutive days or twice a day for at least nine consecutive days,wherein the daily dose of the dextromethorphan is about 40 mg to about 350 mg, and co-administration of the hydroxybupropion, the threohydroxybupropion, the erythrohydroxybupropion or the bupropion, and the dextromethorphan results in a first Cmin of the dextromethorphan that is at least about 20 ng/mL, on the ninth day of consecutive administration, and the first Cmin of the dextromethorphan is at least about 20 times a second Cmin of the dextromethorphan that would result from administering the daily dose of the dextromethorphan without the hydroxybupropion, the threohydroxybupropion, the erythrohydroxybupropion or the bupropion to the human subject for nine consecutive days.
1 Assignment
0 Petitions
Accused Products
Abstract
This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.
211 Citations
30 Claims
-
1. A method of reducing a trough effect of a dextromethorphan in a human subject, wherein the human subject is an extensive metabolizer of the dextromethorphan in need of treatment with the dextromethorphan, comprising co-administering to the human subject a daily dose of a combination, wherein the combination comprises:
-
1) a hydroxybupropion, a threohydroxybupropion, an erythrohydroxybupropion or a bupropion, and 2) the dextromethorphan, once a day for at least nine consecutive days or twice a day for at least nine consecutive days, wherein the daily dose of the dextromethorphan is about 40 mg to about 350 mg, and co-administration of the hydroxybupropion, the threohydroxybupropion, the erythrohydroxybupropion or the bupropion, and the dextromethorphan results in a first Cmin of the dextromethorphan that is at least about 20 ng/mL, on the ninth day of consecutive administration, and the first Cmin of the dextromethorphan is at least about 20 times a second Cmin of the dextromethorphan that would result from administering the daily dose of the dextromethorphan without the hydroxybupropion, the threohydroxybupropion, the erythrohydroxybupropion or the bupropion to the human subject for nine consecutive days. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)
-
Specification